Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of
AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate
cancer that are either chemotherapy naive or have received and progressed on a docetaxel
containing regimen,